| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Protagonist Therapeutics, Inc | Chief R&D Strategy Officer | Common Stock | 167,590 | $4,127,742 | $24.63 | 16 Nov 2022 | Direct |
| Protagonist Therapeutics, Inc | Chief R&D Strategy Officer | Stock Option (right to buy) | 0 | 16 Nov 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| PTGX | Protagonist Therapeutics, Inc | 16 Nov 2022 | 10 | +$231,802 | 4 | Chief R&D Strategy Officer | 17 Nov 2022, 17:24 |
| PTGX | Protagonist Therapeutics, Inc | 28 Feb 2022 | 1 | -$51,449 | 4 | Chief Scientific Officer | 02 Mar 2022, 19:38 |
| PTGX | Protagonist Therapeutics, Inc | 15 Feb 2022 | 2 | $0 | 4 | Chief Scientific Officer | 17 Feb 2022, 18:25 |
| PTGX | Protagonist Therapeutics, Inc | 17 Aug 2021 | 3 | -$694,189 | 4 | Chief Scientific Officer | 19 Aug 2021, 17:49 |